Literature DB >> 27636918

Superficial CD34-positive fibroblastic tumour: a clinicopathological and immunohistochemical study of an additional series.

I Weng Lao1,2, Lin Yu1,2, Jian Wang1,2.   

Abstract

AIMS: To describe an additional series of superficial CD34-positive fibroblastic tumour, a newly described neoplasm, in order to enhance the recognition of an emerging novel entity. METHODS AND
RESULTS: The clinicopathological features and immunophenotypes of 11 cases of superficial CD34-positive fibroblastic tumour were studied. There were eight males and three females, with a median age of 36 years. Tumours occurred in the thigh (n = 4), buttock (n = 3), shoulder (n = 2), upper arm (n = 1), and waist (n = 1). Histologically, all tumours were characterized by relative circumscription, pleomorphic spindled to polygonal cells with variably enlarged bizarre-appearing cells, intranuclear cytoplasmic pseudoinclusions, and extremely low mitotic activity. Immunohistochemically, neoplastic cells showed diffuse and strong expression of CD34 and focal staining of cytokeratin. Follow-up thus far has revealed an indolent clinical behaviour.
CONCLUSIONS: Superficial CD34-positive fibroblastic tumour represents a new member of the family of cutaneous CD34-positive spindle-cell tumours. Familiarity with its clinicopathological characteristics is helpful in avoiding confusion with a variety of cutaneous mesenchymal tumours with overlapping features.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD34; fibroblast; immunohistochemistry; intermediate malignancy; skin

Mesh:

Substances:

Year:  2016        PMID: 27636918     DOI: 10.1111/his.13088

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Superficial CD34-positive fibroblastic tumor: report of two cases and review of literature.

Authors:  Xu Mao; Ying-Ying Sun; Ming-Liang Deng; Tao Ma; Lan Yu
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

2.  Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor.

Authors:  Florian Puls; Jodi M Carter; Nischalan Pillay; Thomas A McCulloch; Vaiyapuri P Sumathi; Pehr Rissler; Henrik Fagman; Magnus Hansson; Fernanda Amary; Roberto Tirabosco; Linda Magnusson; Jenny Nilsson; Adrienne M Flanagan; Andrew L Folpe; Fredrik Mertens
Journal:  Mod Pathol       Date:  2021-12-30       Impact factor: 7.842

Review 3.  WHO Pathology: Highlights of the 2020 Sarcoma Update.

Authors:  Inga-Marie Schaefer; Alessandro Gronchi
Journal:  Surg Oncol Clin N Am       Date:  2022-05-31       Impact factor: 2.402

Review 4.  What's new in fibroblastic tumors?

Authors:  Susan M Armstrong; Elizabeth G Demicco
Journal:  Virchows Arch       Date:  2019-12-11       Impact factor: 4.064

5.  Superficial CD34-positive Fibroblastic Tumour: Unique Subungual Presentation with Confounding Clinical Findings Resembling Fibrokeratoma-like Bowen's Disease.

Authors:  Christophe Perrin; Florence Pedeutour; Bérengère Dadone-Montaudié; Damien Ambrosetti
Journal:  Acta Derm Venereol       Date:  2021-02-11       Impact factor: 3.875

6.  Detailed analysis of a superficial CD34-positive fibroblastic tumor: A case report and review of the literature.

Authors:  Kensaku Yamaga; Akihiro Fujita; Mari Osaki; Satoshi Kuwamoto; Naoko Ishiguro; Tadahito Yamamoto; Hideki Nagashima
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

7.  Superficial CD34-Positive Fibroblastic Tumor: Report of an Extremely Rare Entity.

Authors:  Ebru Zemheri; Ayşe Serap Karadag; İsmail Yılmaz
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

8.  Clinicopathological features of superficial CD34-positive fibroblastic tumor.

Authors:  Li Ding; Wen-Jing Xu; Xiao-Ying Tao; Liang Zhang; Zhao-Gen Cai
Journal:  World J Clin Cases       Date:  2021-04-26       Impact factor: 1.337

9.  Perianal superficial CD34-positive fibroblastic tumor: A case report.

Authors:  Chen-Yan Long; Tao-Li Wang
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.